About   Help   FAQ
Due to maintenance, access to MGI may be intermittent 8:00 AM ET Wed, September 18.
Mammalian Phenotype Ontology Annotations
Query Results - Summary
complement component 3
85 phenotypes from 4 alleles in 11 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
hypoactivity J:211773
increased circulating sodium level J:211773
abnormal blastocyst morphology J:150898
abnormal blood homeostasis J:113463
abnormal dendritic spine morphology J:224676
abnormal female reproductive system physiology J:150898
abnormal hippocampus CA3 region morphology J:224676
abnormal inflammatory response J:113463
abnormal neutrophil morphology J:113463
abnormal spatial working memory J:224676
abnormal synaptic plasticity J:224676
abnormal synaptic vesicle number J:224676
brain inflammation J:123658
decreased anxiety-related response J:224676
decreased cerebral infarction size J:123658
decreased fetal weight J:150898
decreased placental labyrinth size J:150898
decreased spongiotrophoblast size J:150898
decreased susceptibility to autoimmune hemolytic anemia J:145432
enhanced contextual conditioning behavior J:224676
enhanced long term potentiation J:224676
enhanced paired-pulse facilitation J:224676
enhanced spatial learning J:224676
impaired embryo implantation J:150898
increased neuron number J:224676
prolonged estrous cycle J:150898
small placenta J:150898
abnormal eye electrophysiology J:136745
increased susceptibility to bacterial infection J:136745
normal vision/eye phenotype J:136745
involves: 129S4/SvJae
abnormal blood coagulation J:44715
decreased susceptibility to hepatic steatosis J:128218
decreased susceptibility to injury J:128218
decreased urine albumin level J:44715
glomerulonephritis J:44715
involves: 129S4/SvJae * C57BL/6
abnormal cell-mediated immunity J:30152
abnormal enzyme/coenzyme level J:152533
abnormal humoral immune response J:64282
abnormal immune system morphology J:44240
abnormal immune system physiology J:44240
abnormal induced morbidity/mortality J:152533
abnormal intestine morphology J:78613
abnormal liver morphology J:152533
abnormal liver physiology J:152533
abnormal mast cell physiology J:44240
abnormal peripheral nervous system regeneration J:112353
abnormal spleen germinal center morphology J:64282
abnormal tumor necrosis factor level J:44240
decreased circulating alanine transaminase level J:152533
decreased circulating interleukin-6 level J:152533, J:166640
decreased circulating tumor necrosis factor level J:152533
decreased hepatocyte proliferation J:152533
decreased liver regeneration J:152533
decreased mast cell number J:44240
decreased neutrophil cell number J:44240
decreased osteoclast cell number J:166640
decreased spleen germinal center number J:64282
decreased spleen germinal center size J:64282
decreased susceptibility to injury J:120567
decreased vascular permeability J:78613
focal hepatic necrosis J:152533
hepatic steatosis J:152533
normal immune system phenotype J:64282
increased circulating alanine transaminase level J:152533
increased circulating bilirubin level J:152533
increased sensitivity to induced morbidity/mortality J:44240
increased susceptibility to bacterial infection J:30152, J:44240
increased susceptibility to bacterial infection induced morbidity/mortality J:205353
liver inflammation J:30152
decreased liver regeneration J:91917
impaired complement alternative pathway J:177350
either: (involves: 129S2/SvPas * C57BL/6) or (involves: 129X1/SvJ * C57BL/6)
increased susceptibility to bacterial infection J:56193
involves: 129
abnormal intestinal lipid absorption J:87945
decreased body weight J:87945
decreased circulating insulin level J:87945
decreased circulating leptin level J:87945
decreased total body fat amount J:87945
increased circulating free fatty acid level J:87945
increased triglyceride level J:87945
polyphagia J:87945
involves: 129/Sv * C57BL/6
abnormal energy expenditure J:58966, J:60633
abnormal glucose homeostasis J:58966, J:60633
abnormal lipid homeostasis J:58966, J:60633
decreased body weight J:60633
decreased circulating glucose level J:58966, J:60633
decreased circulating insulin level J:60633
decreased circulating leptin level J:58966, J:60633
decreased circulating triglyceride level J:60633
decreased total body fat amount J:58966, J:60633
decreased white adipose tissue amount J:60633
increased brown adipose tissue amount J:58966
increased circulating free fatty acid level J:58966, J:60633
increased triglyceride level J:58966
polyphagia J:58966, J:60633
decreased susceptibility to induced arthritis J:88872
involves: 129P2/OlaHsd * C57BL/6
no abnormal phenotype detected J:45857

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
MGI 6.14
The Jackson Laboratory